GMP-Compliant Human Adipose Tissue-Derived Mesenchymal Stem Cells for Cellular Therapy

  • Hamid-Reza Aghayan
  • Parisa Goodarzi
  • Babak ArjmandEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1283)


Stem cells, which can be derived from different sources, demonstrate promising therapeutic evidences for cellular therapies. Among various types of stem cell, mesenchymal stem cells are one of the most common stem cells that are used in cellular therapy. Human subcutaneous adipose tissue provides an easy accessible source of mesenchymal stem cells with some considerable advantages. Accordingly, various preclinical and clinical investigations have shown enormous potential of adipose-derived stromal cells in regenerative medicine. Consequently, increasing clinical applications of these cells has elucidated the importance of safety concerns regarding clinical transplantation. Therefore, clinical-grade preparation of adipose-derived stromal cells in accordance with current good manufacturing practice guidelines is an essential part of their clinical applications to ensure the safety, quality, characteristics, and identity of cell products. Additionally, GMP-compliant cell manufacturing involves several issues to provide a quality assurance system during translation from the basic stem cell sciences into clinical investigations and applications. On the other hand, advanced cellular therapy requires extensive validation, process control, and documentation. It also evidently elucidates the critical importance of production methods and probable risks. Therefore, implementation of a quality management and assurance system in accordance with GMP guidelines can greatly reduce these risks particularly in the higher-risk category or “more than minimally manipulated” products.


Adipose-derived stem cell Cell therapy Good manufacturing practice Quality assurance 



This work was supported by Brain and spinal Cord Injury Research Center, Tehran University of Medical Sciences (research grant # 85/2160). The authors would like to acknowledge Dr. Abbas Norouzi-Javidan, Dr. Seyed Majid Manavi, Dr. Ramin Heshmat, and Dr. Mohsen Khorshidi for their considerable assistance. We also thank Hanieh Rostam Abadi, Shokouh Salimi, Faezeh Nouraei, and Maryam Kavousi.


  1. 1.
    Thirumala S, Goebel WS, Woods EJ (2009) Clinical grade adult stem cell banking. Organogenesis 5(3):143–154CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Burger S (2003) Current regulatory issues in cell and tissue therapy. Cytotherapy 5(4):289–298CrossRefPubMedGoogle Scholar
  3. 3.
    Prince HM (2004) Cell processing for clinical trials and commercial manufacture. Cell Gene Ther 1:15–21Google Scholar
  4. 4.
    Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, Tchirkov A, Rouard H, Henry C, Splingard M (2010) Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 115(8):1549–1553CrossRefPubMedGoogle Scholar
  5. 5.
    Vishnubalaji R, Al-Nbaheen M, Kadalmani B, Aldahmash A, Ramesh T (2012) Comparative investigation of the differentiation capability of bone-marrow-and adipose-derived mesenchymal stem cells by qualitative and quantitative analysis. Cell Tissue Res 1–9:419–427CrossRefGoogle Scholar
  6. 6.
    Bieback K, Schallmoser K, Klüter H, Strunk D (2008) Clinical protocols for the isolation and expansion of mesenchymal stromal cells. Transfus Med Hemother 35(4):286CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Schäffler A, Büchler C (2007) Concise review: adipose tissue‐derived stromal cells—basic and clinical implications for novel cell‐based therapies. Stem Cells 25(4):818–827CrossRefPubMedGoogle Scholar
  8. 8.
    Lin G, Banie L, Ning H, Bella AJ, Lin CS, Lue TF (2009) Potential of adipose‐derived stem cells for treatment of erectile dysfunction. J Sex Med 6(S3):320–327CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Reichenberger MA, Heimer S, Schaefer A, Lass U, Gebhard MM, Germann G, Leimer U, Köllensperger E, Mueller W (2012) Adipose derived stem cells protect skin flaps against ischemia-reperfusion injury. Stem Cell Rev 1–9:854–862CrossRefGoogle Scholar
  10. 10.
    MacIsaac ZM, Shang H, Agrawal H, Yang N, Parker A, Katz AJ (2011) Long-term in-vivo tumorigenic assessment of human culture-expanded adipose stromal/stem cells. Exp Cell Res 318:416–423CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Mizuno H, Tobita M, Uysal AC (2012) Concise review: adipose‐derived stem cells as a novel tool for future regenerative medicine. Stem Cells 30(5):804–810CrossRefPubMedGoogle Scholar
  12. 12.
    Yarak S, Okamoto OK (2010) Human adipose-derived stem cells: current challenges and clinical perspectives. An Bras Dermatol 85(5):647–656CrossRefPubMedGoogle Scholar
  13. 13.
    Harris LJ, Zhang P, Abdollahi H, Tarola NA, DiMatteo C, McIlhenny SE, Tulenko TN, DiMuzio PJ (2010) Availability of adipose-derived stem cells in patients undergoing vascular surgical procedures. J Surg Res 163(2):e105–e112CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Yamamoto T, Gotoh M, Hattori R, Toriyama K, Kamei Y, Iwaguro H, Matsukawa Y, Funahashi Y (2010) Periurethral injection of autologous adipose-derived stem cells for the treatment of stress urinary incontinence in patients undergoing radical prostatectomy: report of two initial cases. Int J Urol 17(1):75–82CrossRefPubMedGoogle Scholar
  15. 15.
    Brown SG, Harman RJ, Black LL (2012) Adipose-derived stem cell therapy for severe muscle tears in working German shepherds: two case reports. Stem Cell Discov 2(2):41–44CrossRefGoogle Scholar
  16. 16.
    Wang Y, Lian F, Li J, Fan W, Xu H, Yang X, Liang L, Chen W, Yang J (2012) Adipose derived mesenchymal stem cells transplantation via portal vein improves microcirculation and ameliorates liver fibrosis induced by CCl4 in rats. J Transl Med 10(1):133CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Gir P, Oni G, Brown SA, Mojallal A, Rohrich RJ (2012) Human adipose stem cells: current clinical applications. Plast Reconstr Surg 129(6):1277–1290CrossRefPubMedGoogle Scholar
  18. 18.
    Gimble JM, Guilak F, Bunnell BA (2010) Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther 1(2):19–27CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Fekete N, Rojewski MT, Fürst D, Kreja L, Ignatius A, Dausend J, Schrezenmeier H (2012) GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One 7(8):e43255CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Maekawa T, Kimura S, Kasai Y (2005) Development of novel advanced cell and gene therapy and GMP-controlled cell processing. JMAJ 48:81–84Google Scholar
  21. 21.
    Cuende N, Izeta A (2010) Clinical translation of stem cell therapies: a bridgeable gap. Cell Stem Cell 6(6):508–512CrossRefPubMedGoogle Scholar
  22. 22.
    Larijani B, Arjmand B, Amoli MM, Ao Z, Jafarian A, Mahdavi-Mazdah M, Ghanaati H, Baradar-Jalili R, Sharghi S, Norouzi-Javidan A (2011) Establishing a cGMP pancreatic islet processing facility: the first experience in Iran. Cell Tissue Bank 1–7:569–575Google Scholar
  23. 23.
    Burger SR (2000) Design and operation of a current good manufacturing practices cell-engineering laboratory. Cytotherapy 2(2):111–122CrossRefPubMedGoogle Scholar
  24. 24.
    Arjmand B, Emami-Razavi SH, Larijani B, Norouzi-Javidan A, Aghayan HR (2012) The implementation of tissue banking experiences for setting up a cGMP cell manufacturing facility. Cell Tissue Bank 13(4):587–596CrossRefPubMedGoogle Scholar
  25. 25.
    Aghayan HR, Mahdavi-Mazdeh M, Goodarzi P, Arjmand B, Emami-Razavi SH (2010) Coding and traceability in Iran. Cell Tissue Bank 11(4):397–400CrossRefPubMedGoogle Scholar
  26. 26.
    Ilic N, Brooke G, Murray P, Barlow S, Rossetti T, Pelekanos R, Hancock S, Atkinson K (2011) Manufacture of clinical grade human placenta-derived multipotent mesenchymal stromal cells. Methods Mol Biol 698:89–106CrossRefPubMedGoogle Scholar
  27. 27.
    Romagnoli L, Giuntini I, Galgano M, Crosta C, Cavenaghi L, Nolli ML (2011) Cell-based medicinal products and the development of GMP-compliant processes and manufacturing. BMC Proc 5(Suppl 8):O3CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Brooke G, Rossetti T, Pelekanos R, Ilic N, Murray P, Hancock S, Antonenas V, Huang G, Gottlieb D, Bradstock K (2009) Manufacturing of human placenta‐derived mesenchymal stem cells for clinical trials. Br J Haematol 144(4):571–579CrossRefPubMedGoogle Scholar
  29. 29.
    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for cellular therapy position statement. Cytotherapy 8(4):315–317CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Hamid-Reza Aghayan
    • 1
  • Parisa Goodarzi
    • 2
  • Babak Arjmand
    • 3
    Email author
  1. 1.Brain and Spinal Cord Injury Research Center and Chronic Diseases Research Center, Endocrinology and Metabolism Research InstituteTehran University of Medical SciencesTehranIran
  2. 2.Brain and Spinal Cord Injury Research Center, Cellul Fanavaran Danesh Knowledge-Based OrganizationTehran University of Medical SciencesTehranIran
  3. 3.Brain and Spinal Cord Injury Research Center and Chronic Diseases Research Center, Endocrinology and Metabolism Research Institute, Shariati HospitalTehran University of Medical SciencesTehranIran

Personalised recommendations